公开(公告)号：US09750749B2

公开(公告)日：2017-09-05

申请号：US15061727

申请日：2016-03-04

申请人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

发明人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

IPC分类号： A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/557 ,  A61K31/166 ,  A61K31/403 ,  A61K31/5575 ,  A61K31/7105 ,  C12N15/113 ,  A61K31/201 ,  A61K31/713 ,  A61K9/00

CPC分类号： A61K31/557 ,  A61K9/0048 ,  A61K31/166 ,  A61K31/201 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  Y10S514/912

摘要： The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions that includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

公开(公告)号：US20160199386A1

公开(公告)日：2016-07-14

申请号：US15061727

申请日：2016-03-04

申请人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

发明人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

IPC分类号： A61K31/557 ,  A61K9/00 ,  A61K31/7105 ,  A61K31/4439 ,  A61K31/5575 ,  C12N15/113

CPC分类号： A61K31/557 ,  A61K9/0048 ,  A61K31/166 ,  A61K31/201 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  Y10S514/912

摘要： The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

摘要翻译： 本发明涉及治疗和治疗甲状腺疾病症状的方法和组合物。 所述方法包括向具有甲状腺眼病的患者施用干扰透明质酸合成的剂量，该剂量有效地抑制后眼空间中的透明质酸合成。 药物组合物帽包括适用于眼科递送的载体和干扰透明质酸合成的药剂。 还公开了联合疗法。

公开(公告)号：US09320723B2

公开(公告)日：2016-04-26

申请号：US13099991

申请日：2011-05-03

申请人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

发明人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

IPC分类号： A61K31/403 ,  A61K31/166 ,  A61K31/201 ,  A61K31/4439 ,  A61K31/713 ,  A61K9/00

CPC分类号： A61K31/557 ,  A61K9/0048 ,  A61K31/166 ,  A61K31/201 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  Y10S514/912

摘要： The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

摘要翻译： 本发明涉及治疗和治疗甲状腺疾病症状的方法和组合物。 所述方法包括向具有甲状腺眼病的患者施用干扰透明质酸合成的剂量，该剂量有效地抑制后眼空间中的透明质酸合成。 药物组合物帽包括适用于眼科递送的载体和干扰透明质酸合成的药剂。 还公开了联合疗法。

公开(公告)号：US20120015001A1

公开(公告)日：2012-01-19

申请号：US13099991

申请日：2011-05-03

申请人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

发明人： Richard P. Phipps ,  Naxin Guo ,  Steven Feldon

IPC分类号： A61K38/18 ,  A61K9/00 ,  A61K31/201 ,  A61K38/00 ,  A61K31/166 ,  A61K38/17 ,  A61P27/02 ,  A61K31/713 ,  A61K31/4439 ,  B82Y5/00

CPC分类号： A61K31/557 ,  A61K9/0048 ,  A61K31/166 ,  A61K31/201 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  Y10S514/912

摘要： The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

摘要翻译： 本发明涉及治疗和治疗甲状腺疾病症状的方法和组合物。 所述方法包括向具有甲状腺眼病的患者施用干扰透明质酸合成的剂量，该剂量有效地抑制后眼空间中的透明质酸合成。 药物组合物帽包括适用于眼科递送的载体和干扰透明质酸合成的药剂。 还公开了联合疗法。